Zacks Research Issues Positive Estimate for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research increased their Q4 2025 earnings estimates for Corcept Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings per share of $0.54 for the quarter, up from their previous estimate of $0.53. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2026 earnings at $0.73 EPS, Q4 2026 earnings at $0.73 EPS and FY2026 earnings at $2.47 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.14. The business had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.28 EPS.

A number of other research analysts also recently issued reports on CORT. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Finally, Truist Financial raised their price objective on Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research note on Monday, September 30th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $65.25.

Corcept Therapeutics Trading Down 0.2 %

Shares of CORT stock opened at $58.91 on Thursday. The company has a market cap of $6.17 billion, a P/E ratio of 46.66 and a beta of 0.56. Corcept Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $62.22. The stock has a 50 day simple moving average of $54.85 and a two-hundred day simple moving average of $45.44. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70.

Insiders Place Their Bets

In other news, insider Joseph Douglas Lyon sold 1,411 shares of the stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $56.72, for a total value of $80,031.92. Following the completion of the sale, the insider now owns 8,494 shares in the company, valued at $481,779.68. This represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.88, for a total transaction of $131,736.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,011 shares of company stock valued at $1,951,268. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jacobs Levy Equity Management Inc. increased its position in shares of Corcept Therapeutics by 40.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,223,781 shares of the biotechnology company’s stock valued at $56,637,000 after purchasing an additional 352,947 shares during the last quarter. FMR LLC increased its holdings in Corcept Therapeutics by 24.6% during the third quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company’s stock worth $63,122,000 after buying an additional 269,074 shares during the last quarter. M&G PLC bought a new stake in Corcept Therapeutics in the third quarter worth about $11,173,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Corcept Therapeutics by 20.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 859,563 shares of the biotechnology company’s stock valued at $39,781,000 after acquiring an additional 143,507 shares during the last quarter. Finally, abrdn plc grew its position in shares of Corcept Therapeutics by 27.1% during the 3rd quarter. abrdn plc now owns 666,952 shares of the biotechnology company’s stock valued at $30,867,000 after acquiring an additional 142,310 shares during the period. Hedge funds and other institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.